Immunologic control of tumors by in vivo Fcγ receptor-targeted antigen loading in conjunction with double-stranded RNA-mediated immune modulation

Journal of Immunology

Volumn 176, Issue 3, 2006, Pages 1363-1374

  Bot, Adrian ^a,e   Smith, Dan ^a,b   Phillips, Bill ^a,b   Bot, Simona ^a   Bona, Constantin ^c   Zaghouani, Habib ^d  

^a Alliance Pharmaceutical Corporation   (United States)

^b MultiCell Immunotherapeutics   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MISSOURI   (United States)

^e MannKind Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; DOUBLE STRANDED RNA; EPITOPE; FC RECEPTOR; IMMUNOGLOBULIN IDIOTYPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGENIC VARIATION; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; GENE TARGETING; HEMATOLOGIC MALIGNANCY; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; IN VIVO STUDY; MEMORY CELL; METASTASIS; MOUSE; NONHUMAN; ONCOVIRINAE; PRIORITY JOURNAL; PROTEIN MOTIF; TUMOR IMMUNITY;

EID: 31144456176     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.3.1363     Document Type: Article

References (45)

1. Dunn, G. P., L. J. Old, and R. D. Schreiber. 2004. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21: 137-148.
2. Houghton, A. N., and J. A. Guevara-Patino. 2004. Immune recognition of self in immunity against cancer. J. Clin. Invest. 114: 468-471.
3. + Tregs and immune control. J. Clin. Invest. 114: 1209-1217.
4. Brack, C., M. Hirama, R. Lenhard-Schuller, and S. Tonegawa. 1978. Molecular construction (recombination, mutation) of Ag rec A complete immunoglobulin gene is created by somatic recombination. Cell 15: 1-14.
5. Oudin, J., and M. Michel. 1963. Une nouvelle forme d'allotypie des globulines gamma du serum de lapin, apparenment liée a la fonction et a la spécificité anticorps. C. R. Hebd. Seances Acad. Sci. (Paris) 257: 805-808.
6. Jerne, N. K. 1974. Towards a network theory of the immune system. Ann. Immunol. Inst. Pasteur (Paris) 125 C(1-2): 373-389.
7. Cazenave, P. A. 1977. Idiotypic-anti-idiotypic regulation of antibody synthesis in rabbits. Proc. Natl. Acad. Sci. USA 74: 5122-5125.
8. Bona, C., and W. E. Paul. 1979. Cellular basis of regulation of expression of idiotype. I. T-suppressor cells specific for MOPC 460 idiotype regulate the expression of cells secreting anti-TNP antibodies bearing 460 idiotype. J. Exp. Med. 149: 592-600.
9. Sakato, N., M. Semma, H. N. Eisen, and T. Azuma. 1982. A small hypervariable segment in the variable domain of an immunoglobulin light chain stimulates formation of anti-idiotypic suppressor T cells. Proc. Natl. Acad. Sci. USA 79: 5396-5400.
10. Furumoto, H., and M. Irahara. 2002. Human papilloma virus (HPV) and cervical cancer. J. Med. Invest. 49: 124-133.
11. Bréchot, C. 2004. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 127(5 Suppl 1): S56-S61.
12. Young, L. S., and P. G. Murray. 2003. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 22: 5108-5121.
13. Sheu, B.-C., R.-H. Lin, H.-C. Lien, H.-N. Ho, S.-M. Hsu, and S.-C. Huang. 2001. Predominant Th2/Tc2 polarity of tumor infiltrating lymphocytes in human cervical cancer. J. Immunol. 167: 2972-2978.
14. Ghim, S. J., J. Sundberg, G. Delgado, and A. B. Jenson. 2001. The pathogenesis of advanced cervical cancer provides the basis for an empirical therapeutic vaccine. Exp. Mol. Pathol. 71: 181-185.
15. + subsets. Br. J. Haematol. 96: 338-345.
16. Yi, Q., A. Osterborg, S. Bergenbrant, H. Mellstedt, G. Holm, and A. K. Lefvert. 1995. Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood 86: 3043-3049.
17. Yi, Q. Vaccines for Hematological Malignancies. In Handbook of Cancer Vaccines. M. A. Morse, T. M. Clay, and H. K. Lyerly, eds. Humana Press, Totowa, NJ, p. 425-449.
18. Yi, Q., R. Desikan, B. Barlogie, and N. Munshi. 2002. Optimizing dendritic cell-based immunotherapy in multiple myeloma. Br. J. Haematol. 117: 297-305.
19. Kaminski, M. S., K. Kitamura, D. G. Maloney, and R. Levy. 1987. Idiotype vaccination against murine B cell lymphoma: inhibition of tumor immunity by free idiotype protein. J. Immunol. 138: 1289-1296.
20. Thrush, G. R., A. W. Butch, and S. P. Lerman. 1989. CD8 suppressor cell activity and its effect on CD4 helper cell-dependent growth of SJL/J B-cell lymphomas. Cell. Immunol. 122: 555-562.
21. Chakrabarti, D., and S. K. Ghosh. 1992. Induction of syngeneic cytotoxic T lymphocytes against a B cell tumor. III. MHC class I-restricted CTL recognizes the processed form(s) of idiotype. Cell. Immunol. 144: 455-464.
22. Dhodapkar, M. V., J. Krasovsky, and K. Olson. 2002. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc. Natl. Acad. Sci. USA 99: 13009-13013.
23. Zaghouani, H., R. Steinman, R. Nonacs, H. Shah, W. Gerhard, and C. Bona. 1993. Presentation of a viral T cell epitope expressed in the CDR3 region of a self immunoglobulin molecule. Science 259: 224-227.
24. Zanetti, M., F. Rossi, P. Lanza, G. Filaci, R. H. Lee, and R. Billetta. 1992. Theoretical and practical aspects of antigenized antibodies. Immunol. Rev. 130: 125-150.
25. Brumeanu, T. D., W. J. Swiggard, R. M. Steinman, C. A. Bona, and H. Zaghouani. 1993. Efficient loading of identical viral peptide onto class II molecules by antigenized immunoglobulin and influenza virus. J. Exp. Med. 178: 1795-1799.
26. Billetta, R., M. R. Hollingdale, and M. Zanetti. 1991. Immunogenicity of an engineered internal image antibody. Proc. Natl. Acad. Sci. USA 88: 4713-4717.
27. Li, S., V. Polonis, H. Isobe, H. Zaghouani, R. Guinea, T. Moran, C. Bona, and P. Palese. 1993. Chimeric influenza virus induces neutralizing antibodies and cytotoxic T cells against human immunodeficiency virus type 1. J. Virol. 67: 6659-6666.
28. Zaghouani, H., Y. Kuzu, H. Kuzu, T. D. Brumeanu, W. J. Swiggard, R. M. Steinman, and C. A. Bona. 1993. Contrasting efficacy of presentation by major histocompatibility complex class I and class II products when peptides are administered within a common protein carrier, self immunoglobulin. Eur. J. Immunol. 23: 2746-2750.
29. Kuzu, Y., H. Kuzu, H. Zaghouani, and C. Bona. 1993. Priming of cytotoxic T lymphocytes at various stages of ontogeny with transfectoma cells expressing a chimeric Ig heavy chain gene bearing an influenza virus nucleoprotein peptide. Int. Immunol. 5: 1301-1307.
30. Wallace, P. K., K. Y. Tsang, J. Goldstein, P. Correale, T. M. Jarry, J. Schlom, P. M. Guyre, M. S. Ernstoff, and M. W. Fanger. 2001. Exogenous antigen targeted to FcγRI on myeloid cells is presented in association with MHC class I. J. Immunol. Methods 248: 183-194.
31. Kalergis, A. M., and J. V. Ravetch. 2002. Inducing tumor immunity through the selective engagement of activating Fcγ receptors on dendritic cells. J. Exp. Med. 195: 1653-1659.
32. Takai, T., M. Li, D. Sylvestre, R. Clynes, and J. V. Ravetch. 1994. FcRγ chain deletion results in pleiotrophic effector cell defects. Cell 76: 519-529.
33. Nakamura, A., T. Yuasa, A. Ujike, M. Ono, T. Nukiwa, J. V. Ravetch, and T. Takai. 2000. Fcγ receptor IIB-deficient mice develop Goodpasture's syndrome upon immunization with type IV collagen: a novel murine model for autoimmune glomerular basement membrane disease. J. Exp. Med. 191: 899-906.
34. Rotzschke, O., K. Falk, K. Deres, H. Schild, M. Norda, J. Metzger, G. Jung, and H. G. Rammensee. 1990. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature 348: 252-254.
35. Bot, A., S. Bot, and C. A. Bona. 1998. Protective role of γ interferon during the recall response to influenza virus. J. Virol. 72: 6637-6645.
36. Wang, L., D. Smith, S. Bot, L. Dellamary, A. Bloom, and A. Bot. 2002. Non-coding RNA danger motifs bridge innate and adaptive immunity and are potent adjuvants for vaccination. J. Clin. Invest. 110: 1175-1184.
37. Köhler, G., and C. Milstein. 1976. Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur. J. Immunol. 6: 511-519.
38. Wang, P., P. Palese, and R. E. O'Neill. 1997. The NPI-1/NPI-3 (karyopherin α) binding site on the influenza a virus nucleoprotein NP is a nonconventional nuclear localization signal. J. Virol. 71: 1850-1856.
39. Brodeur, B. R., P. Tsang, and Y. Larose. 1984. Parameters affecting ascites tumour formation in mice and monoclonal antibody production. J. Immunol. Methods 71: 265-272.
40. McGaha, T. L., B. Sorrentino, and J. V. Ravetch. 2005. Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science 307: 590-593.
41. Dhodapkar, K. M., J. L. Kaufman, M. Ehlers, D. K. Banerjee, E. Bonvini, S. Koenig, R. M. Steinman, J. V. Ravetch, and M. V. Dhodapkar. 2005. Selective blockade of inhibitory Fcγ receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc. Natl. Acad. Sci. USA 102: 2910-2915.
42. + T cells secreting Th1 or Th2 cytokines. Immunity 2: 271-279.
43. Bot, A., K. A. Smith, and M. von Herrath. 2004. Molecular and cellular control of T1/T2 immunity at the interface between antimicrobial defense and immune pathology. DNA Cell Biol. 23: 341-350.
44. Victor-Kobrin, C., and C. A. Bona. 1989. The molecular origin of regulatory idiotypes. Int. Rev. Immunol. 5: 117-129.
45. Hansson, L., H. Rabbani, J. Fagerberg, A. Österborg, and H. Mellstedt. 2003. T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma. Blood 101: 4930-4936.